198 related articles for article (PubMed ID: 28413374)
1. Discrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics.
Lindahl A; Heuchel R; Forshed J; Lehtiö J; Löhr M; Nordström A
Metabolomics; 2017; 13(5):61. PubMed ID: 28413374
[TBL] [Abstract][Full Text] [Related]
2. LC-MS/MS and SWATH based serum metabolomics enables biomarker discovery in pancreatic cancer.
Xiong Y; Shi C; Zhong F; Liu X; Yang P
Clin Chim Acta; 2020 Jul; 506():214-221. PubMed ID: 32243985
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature.
Davis VW; Schiller DE; Eurich D; Bathe OF; Sawyer MB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S415-23. PubMed ID: 23096698
[TBL] [Abstract][Full Text] [Related]
4. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
5. Distinct serum metabolomics profiles associated with malignant progression in the KrasG12D mouse model of pancreatic ductal adenocarcinoma.
LaConti JJ; Laiakis EC; Mays AD; Peran I; Kim SE; Shay JW; Riegel AT; Fornace AJ; Wellstein A
BMC Genomics; 2015; 16 Suppl 1(Suppl 1):S1. PubMed ID: 25923219
[TBL] [Abstract][Full Text] [Related]
6. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma.
Sahni S; Pandya AR; Hadden WJ; Nahm CB; Maloney S; Cook V; Toft JA; Wilkinson-White L; Gill AJ; Samra JS; Dona A; Mittal A
Int J Cancer; 2021 Mar; 148(6):1508-1518. PubMed ID: 33128797
[TBL] [Abstract][Full Text] [Related]
7. Malignancy in chronic pancreatitis: analysis of diagnostic procedures and proposal of a clinical algorithm.
Rückert F; Brussig T; Kuhn M; Kersting S; Bunk A; Hunger M; Saeger HD; Niedergethmann M; Post S; Grützmann R
Pancreatology; 2013; 13(3):243-9. PubMed ID: 23719595
[TBL] [Abstract][Full Text] [Related]
8. Identification of potential pancreatic cancer serum markers: Increased sialyl-Lewis X on ceruloplasmin.
Balmaña M; Sarrats A; Llop E; Barrabés S; Saldova R; Ferri MJ; Figueras J; Fort E; de Llorens R; Rudd PM; Peracaula R
Clin Chim Acta; 2015 Mar; 442():56-62. PubMed ID: 25595436
[TBL] [Abstract][Full Text] [Related]
9. Untargeted metabolomics characterization of the resectable pancreatic ductal adenocarcinoma.
Cao YY; Guo K; Zhao R; Li Y; Lv XJ; Lu ZP; Tian L; Ren S; Wang ZQ
Digit Health; 2023; 9():20552076231179007. PubMed ID: 37312938
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin as a discriminating marker for pancreatic cancer and chronic pancreatitis.
Rychlíková J; Vecka M; Jáchymová M; Macášek J; Hrabák P; Zeman M; Vávrová L; Řoupal J; Krechler T; Ák A
Cancer Biomark; 2016 Jun; 17(1):55-65. PubMed ID: 27314293
[TBL] [Abstract][Full Text] [Related]
11. Potential Metabolite Biomarkers for Early Detection of Stage-I Pancreatic Ductal Adenocarcinoma.
Cao Y; Zhao R; Guo K; Ren S; Zhang Y; Lu Z; Tian L; Li T; Chen X; Wang Z
Front Oncol; 2021; 11():744667. PubMed ID: 35127469
[TBL] [Abstract][Full Text] [Related]
12. Serum Metabolite Biomarkers for Pancreatic Tumors: Neuroendocrine and Pancreatic Ductal Adenocarcinomas-A Preliminary Study.
Skubisz K; Dąbkowski K; Samborowska E; Starzyńska T; Deskur A; Ambrozkiewicz F; Karczmarski J; Radkiewicz M; Kusnierz K; Kos-Kudła B; Sulikowski T; Cybula P; Paziewska A
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370852
[TBL] [Abstract][Full Text] [Related]
13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
14. Specific increase in serum core-fucosylated haptoglobin in patients with chronic pancreatitis.
Ueda M; Kamada Y; Takamatsu S; Shimomura M; Maekawa T; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kobayashi Y; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
Pancreatology; 2016; 16(2):238-43. PubMed ID: 26897254
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of targeted metabolomics: dominance-based rough set approach versus orthogonal partial least square-discriminant analysis.
Blasco H; Błaszczyński J; Billaut JC; Nadal-Desbarats L; Pradat PF; Devos D; Moreau C; Andres CR; Emond P; Corcia P; Słowiński R
J Biomed Inform; 2015 Feb; 53():291-9. PubMed ID: 25499899
[TBL] [Abstract][Full Text] [Related]
16. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
[TBL] [Abstract][Full Text] [Related]
17. Novel Metabolomics Serum Biomarkers for Pancreatic Ductal Adenocarcinoma by the Comparison of Pre-, Postoperative and Normal Samples.
Zhang X; Shi X; Lu X; Li Y; Zhan C; Akhtar ML; Yang L; Bai Y; Zhao J; Wang Y; Yao Y; Li Y; Nie H
J Cancer; 2020; 11(16):4641-4651. PubMed ID: 32626510
[No Abstract] [Full Text] [Related]
18. Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.
Maekawa T; Kamada Y; Ebisutani Y; Ueda M; Hata T; Kawamoto K; Takamatsu S; Mizutani K; Shimomura M; Sobajima T; Fujii H; Nakayama K; Nishino K; Yamada M; Kumada T; Ito T; Eguchi H; Nagano H; Miyoshi E
World J Gastroenterol; 2016 May; 22(17):4403-10. PubMed ID: 27158210
[TBL] [Abstract][Full Text] [Related]
19. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
[TBL] [Abstract][Full Text] [Related]
20. Untargeted Metabolomics for the Diagnosis of Exocrine Pancreatic Insufficiency in Chronic Pancreatitis.
Díaz C; Jiménez-Luna C; Diéguez-Castillo C; Martín A; Prados J; Martín-Ruíz JL; Genilloud O; Vicente F; Pérez Del Palacio J; Caba O
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577799
[No Abstract] [Full Text] [Related]
[Next] [New Search]
